cloudfront
  • info@reportsandmarkets.com
  • +44-020-3286-9338 (UK) +1-214-377-1121 (US)
  • Sign In
  • Register

PharmaceuticalsResverlogix Corp. (RVX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • RnM783627
  • |
  • 22 September, 2016
  • |
  • Global
  • |
  • 34 pages
  • |
  • GlobalData
  • |
  • Pharmaceuticals

Summary

Resverlogix Corp. (Resverlogix) is an epigenetics company which focuses on the development of small molecule therapeutics for Bromodomain and ExtraTerminal Domain (BET) inhibition. The company’s lead product RVX-208 (apabetalone), is a BET inhibitor under phase III clinical trial. RVX-208 is being developed for high-risk cardiovascular disease patients with diabetes mellitus and low HDL; and Alzheimer's disease. Resverlogix utilizes an epigenetics drug development platform, BET technology, to target BET proteins and identify small molecule candidates that specifically bind to BET bromodomains and regulate gene expression. The company has a representative office in San Francisco, California, the US. Resverlogix is headquartered in Calgary, Alberta, Canada.

Resverlogix Corp. (RVX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Resverlogix Corp., Pharmaceuticals & Healthcare, Deals By Year, 2010 to YTD 2016 5
Resverlogix Corp., Pharmaceuticals & Healthcare Deals By Type, 2010 to YTD 2016 6
Resverlogix Corp., Pharmaceuticals & Healthcare, Deals By Region, 2010 to YTD 2016 7
Resverlogix Corp., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2010 to YTD 2016 8
Resverlogix Corp., Pharmaceuticals & Healthcare, Deals Summary, 2010 to YTD 2016 9
Resverlogix Corp., Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Resverlogix Enters into Research Agreement with Emerald Logic 10
Licensing Agreements 11
Resverlogix Enters into Licensing Agreement with Shenzhen Hepalink Pharma 11
Resverlogix Terminates Agreement with RVX Therapeutics 12
Equity Offering 13
Resverlogix Raises USD41.4 Million in Private Placement of Units 13
Resverlogix Raises USD2 Million in Private Placement of Shares 15
Resverlogix Completes Private Placement Of Units For US$1.5 Million 16
Resverlogix Completes First Tranche Of Private Placement Of Shares For US$0.2 Million 18
Resverlogix Completes Private Placement Of Shares For US$16.9 Million 20
Resverlogix Completes Public Offering Of Units For US$13 Million 22
Resverlogix Completes Public Offering Of US$10 Million 24
Resverlogix Completes Private Placement Of US$0.18 Million 26
Resverlogix Completes Private Placement For US$9 Million 28
Resverlogix Completes Second Tranche Private Placement Of US$31 Million 30
Resverlogix Corp. - Key Competitors 31
Key Employees 32
Locations And Subsidiaries 33
Head Office 33
Other Locations & Subsidiaries 33
Appendix 34
Methodology 34
About GlobalData 34
Contact Us 34
Disclaimer 34





Single User License (PDF)

  • This license allows for use of a publication by one person.
  • This person may not print out a single copy of the publication.
  • This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
  • This person cannot share the publication (or any information contained therein) with any other person or persons.
  • Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
  • Customers who infringe these license terms are liable for a Global license fee.

 

Site License (PDF)*

  • This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
  • These users may print out a single copy of the publication.
  • These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
  • These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
  • Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
  • Customers who infringe these license terms are liable for a Global license fee.

 

Global License (PDF)*

  • This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
  • Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
  • These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.




REPORT YOU MIGHT BE INTERESTED

Purchase this Report

$250.00
$500.00
$750.00
167.88
335.75
503.63
230.05
460.10
690.15
30,285.00
60,570.00
90,855.00
16,578.35
33,156.70
49,735.05
Add To Cart Credit card Logo

Related Reports


Reason to Buy